OAKLAND PARK, FL--(Marketwired - Jun 2, 2016) - BioStem Technologies, Inc. ("BioStem" or the "Company") (
BioStem Pharmaceuticals is a pharmaceutical distribution and manufacturing company that is focused on the redistribution of Active Pharmaceutical Ingredients as well as development and approval of New Drug Applications. The FDA Establishment Registration and Labeler Code allows BioStem Pharmaceuticals to manufacture and distribute pharmaceuticals products in the United States.
The Office of Compliance, Immediate Office oversees the electronic Drug Registration and Listing System, a key component of the Food and Drug Administration's ability to monitor drug safety. Section 510 of the Federal Food, Drug, and Cosmetic Act requires firms that manufacture, prepare, propagate, compound, or process drugs in the U.S. or that are offered for import into the U.S. to register with the FDA. These domestic and foreign firms must at the time of registration, list all drugs manufactured, prepared, propagated, compounded, or processed for commercial distribution in the U.S.
Joe Esposito, President of BioStem Pharmaceuticals, went on to say, "We are very excited to have this process completed. This now gives us the ability to move forward with the development and manufacturing of strategically chosen products that have been mapped out in our business plan."
About BioStem Technologies, Inc. (
Forward-Looking Statements Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
Contact Information:
Contact:
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtech.com
Email:info@biostemtech.com
Twitter: @BioStemTech
Facebook: BioStem Technologies